The company aims to develop new antibody-drug conjugates for cancer treatment. Credit: Max Acronym / Shutterstock.

France-based biopharmaceutical company Adcytherix has announced its launch with seed funding of €30m ($32.2m) aimed at developing new antibody-drug conjugates (ADCs) for cancer treatment.

The company will focus on the development of ADCs targeting diseases with significant unmet medical needs.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The financial injection marks a significant milestone for Adcytherix, which was founded by Jack Elands and Pontifax Venture Capital. Xavier Preville and Carsten Dehning are co-founders.

Jack Elands is CEO, Dehning is chief financial officer and Preville is research and preclinical development vice-president and head.

The seed funding round was spearheaded by Pontifax and received support from a consortium of top-tier life science investors, including RA Capital Management, Pureos Bioventures and Dawn Biopharma — a platform under the control of global investment firm KKR.

See Also:

The company’s management team also contributed to the seed funding.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Elands stated: “Our new company has as its objective to meet the most urgent need of patients by developing a next generation of ADCs. We are excited that the top tier investors and business partners that supported us before joined us again to help us achieve our goals.”

Adcytherix also welcomed new members to its supervisory committee: Ran Nussbaum and Ohad Hammer from Pontifax, Iyona Rajkomar of Dawn Biopharma, Ximing Ding of Pureos Bioventures and Matthew Hammond of RA Capital Management.

Nussbaum stated: “We are excited to be part of this new adventure with a superb leadership that worked with us before.

“ADCs will play a major role in the future of oncology. The team that is leading the company and the syndicate that will support Adcytherix aim to build a well-differentiated franchise in the field.”

The Adcytherix founding team previously established and sold Emergence Therapeutics to Eli Lilly and Company.